Related Experiment Video
Updated: Aug 17, 2026
Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting
Published on: March 28, 2025
Changes in platelet aggregation during cardiopulmonary bypass: comparison of poly-2-methoxyethylacrylate and heparin
Hitoshi Izuha1, Momoe Hattori, Tsuguo Igari
1Division of Surgery, Fukushima Medical University Hospital, 1-Hikarigaoka, Fukushima, 960-1295, Japan. h-izuha@fmu.ac.jp
Insights
This study compared a novel poly-2-methoxyethylacrylate (X coating) cardiopulmonary bypass system against standard heparin coating. Both coatings demonstrated similar efficacy in reducing platelet aggregation during cardiac surgery.
Area of Science:
- Biomaterials Science
- Cardiovascular Surgery
- Hematology
Background:
- Cardiopulmonary bypass (CPB) systems utilize coated circuits, but their impact on platelet aggregation is under-investigated.
- Biocompatible materials are crucial for minimizing adverse events during CPB procedures.
Purpose of the Study:
- To evaluate the efficacy of a poly-2-methoxyethylacrylate (X coating) in suppressing platelet aggregation during CPB.
- To compare the performance of X coating against conventional heparin coating in CPB systems.
Main Methods:
- A comparative clinical study involving 19 adult patients undergoing valve surgery.
- Patients were divided into two groups: X coating and heparin (H) coating.
- Platelet aggregation (PATI) and activation markers (beta-thromboglobulin, PF4) were measured at multiple time points.
Main Results:
- Platelet aggregation was reduced during CPB in both groups.
- Evidence of platelet activation was observed during CPB.
- The X coating showed comparable results to heparin coating in mitigating platelet aggregation.
Conclusions:
- Poly-2-methoxyethylacrylate (X coating) offers a comparable alternative to heparin coating for CPB circuits.
- The study suggests X coating effectively suppresses platelet aggregation during cardiopulmonary bypass.
- Further research may explore the long-term clinical benefits of X coating in cardiac surgery.
Abstract:
At present, there are various biomaterials that have high biocompatibility. In particular, there are many types of coated circuits in cardiopulmonary bypass (CPB) systems. However, only a few clinical studies have investigated platelet aggregation caused by these coated circuits. In this study, a CPB system coated with poly-2-methoxyethylacrylate (X coating) was used to ascertain whether platelet aggregation could be suppressed during CPB, and a comparison was made between X coating and ordinary (covalently bonded) heparin coating. The subjects were 19 adult patients who were scheduled to undergo valve replacement or valvuloplasty. They were divided into two groups: group X (X coating) and group H (heparin coating). The platelet aggregation threshold index (PATI, grading curve) and beta-thromboglobulin and plalelet factor IV levels were assessed preoperatively (control), 5 min after heparin administration, 10 and 60 min after the start of CPB, and 0 and 2 h after the end of CPB. The results indicated that platelet aggregation was reduced during CPB and that platelets were activated. The changes in platelet aggregation associated with the X coating were shown to be similar to those associated with heparin coating.
